Biotech Alert: Searches spiking for these stocks today | Markets Insider

Rakovina Therapeutics Inc. has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments, potentially reshaping oncology research.

The FDA is set to decide on Biogen and Eisai's Leqembi for monthly intravenous maintenance in early Alzheimer's disease, potentially improving patient convenience.

The FDA granted Breakthrough Therapy Designation to Gilead's Trodelvy for extensive-stage small cell lung cancer (ES-SCLC) after platinum-based chemotherapy, based on promising results from the TROPiCS-03 study.

Oncolytics Biotech presented data at the ASCO GI Symposium, highlighting pelareorep's potential in treating relapsed anal and metastatic pancreatic cancers.

BridgeBio Pharma's Attruby (acoramidis) receives FDA approval for transthyretin amyloidosis cardiomyopathy (ATTR-CM), reducing cardiovascular death and hospitalization.

Roche will acquire Poseida Therapeutics for $1.0 billion, expanding its CAR-T therapy portfolio, targeting hematological malignancies, solid tumors, and autoimmune diseases.

Seraxis received FDA IND allowance for SR-02, a stem cell-derived islet replacement therapy, marking a potential functional cure for insulin-requiring diabetes.

AbbVie is set to acquire Cerevel Therapeutics for $8.7 billion, bolstering its neuroscience pipeline with candidates targeting schizophrenia, Parkinson's disease, and mood disorders.

Viva BioInnovator's portfolio companies, AcuraStem, ABM Therapeutics, and QureBio, have made notable progress in their respective fields. AcuraStem has entered a license agreement with Takeda for ALS treatment development, ABM Therapeutics' ABM-1310 received FDA Fast Track designation for GBM treatment, and QureBio's Q-1802 project was selected for the Shanghai 2023 Sci-Tech SME Innovation Fund.

Iterum Therapeutics completed a late-cycle meeting with the FDA regarding its sulopenem etzadroxil/probenecid application for uncomplicated urinary tract infections.